We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quotient and GE Healthcare Extends Agreement to Complete Transfer into New Radiochemistry Facility in Cardiff
News

Quotient and GE Healthcare Extends Agreement to Complete Transfer into New Radiochemistry Facility in Cardiff

Quotient and GE Healthcare Extends Agreement to Complete Transfer into New Radiochemistry Facility in Cardiff
News

Quotient and GE Healthcare Extends Agreement to Complete Transfer into New Radiochemistry Facility in Cardiff

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Quotient and GE Healthcare Extends Agreement to Complete Transfer into New Radiochemistry Facility in Cardiff"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

An extension to the manufacturing transfer agreement that was put in place with GE Healthcare (GEHC) as part of the Quotient Bioresearch acquisition of Amersham Radiolabelling Services, the custom radiochemical synthesis operations of GE Healthcare, has now been agreed.

This extension will assure customers of a smooth transition and uninterrupted supply of carbon-14 labelled compounds during the move of Amersham Radiolabelling Services from the existing site to its new facility in Cardiff this Spring.

At the time of the acquisition in June 2009, Quotient formed its Chemistry & Metabolism business unit and announced a £15 million investment in a new facility in Cardiff. The facility will be equipped with world-class technology and operate to the highest environmental and safety standards. It will house the largest and most experienced team of radiosynthesis chemists in the world. Now, a timescale for completion and the transfer of production has been confirmed for Spring 2010.

Quotient’s ‘synthesis to clinic’ capability allows it to provide a seamless service from synthesis of a compound to clinical report for pharmaceutical and biotechnology clients engaged in studies containing radiolabelled compounds. This integrated service simplifies the procurement of regulatory and non-regulatory studies, resulting in shorter development times and associated efficiencies.
Advertisement